Huhtamaki's proprietary breakthrough high-precision technology delivers home compostable paper-based coffee capsules for Nespresso and millions of coffee lovers
Huhtamaki, a global sustainable packaging solutions provider, started an exclusive partnership with one of the largest coffee brands, Nespresso, in early 2021 to innovate a sustainable home-compostable paper-based coffee capsule. The powerful collaboration, used a lean approach to product and process development, accelerating the time to market in record time. Huhtamaki's proprietary high-precision technology allows wood fibers to be molded into intricate shapes with high-precision tolerances to a fraction of a millimeter.
The home compostable paper-based coffee capsule was launched by Nespresso in France yesterday, November 21, 2022. It is a significant development in innovation for the circular economy and a leap forward for consumers around the world.
- Huhtamaki's proprietary high-precision technology for smooth molded fiber transforms wood pulp fibers into high performance packing solutions which can be applied to a myriad of different consumer applications.
- The proprietary high-precision technology for smooth molded fiber is part of the company’s blueloop™ brand promise, reflecting its 2030 sustainability ambition.
- The home compostable paper-based Nespresso coffee capsules were first launched in Paris, France, on 21stNovember 2022. The capsules will initially be piloted with consumers in France and Switzerland in spring 2023 before being introduced more widely.
- The paper-based coffee capsules are made from wood fiber, responsibly sourced from European forests. They have been independently certified by TÜV – as home compostable and compostable in food waste collection schemes.
- The coffee capsules protect coffee quality and freshness while offering the required functionality that delivers the high-quality coffee for which the brand is known – with no compromise on the taste experience.
"We are delighted to have partnered with Nespresso on a unique home compostable paper-based capsule designed for circularity. This breakthrough innovation is the result of combining fiber, a natural renewable material, with our proprietary high precision technology, creating a sustainable alternative for Nespresso lovers. The capsules will be produced in line with our blueloop™ brand promise, which incorporates our commitment to design for circularity, to be operationally carbon neutral, and to responsibly source our materials in line with our 2030 strategy," says Charles Héaulmé, President and CEO at Huhtamaki.
Huhtamaki is committed to delivering sustainable packaging solutions with a positive impact on the environment. It is pro-actively working with innovative consumer brands to redesign the future of packaging. This partnership's success demonstrates how innovation and collaboration can deliver for the circular economy, and tackle climate action by becoming carbon neutral while not forgetting other environmental and social aspects of sustainability.
We see this technology as a paradigm shift in how we can use renewable wood fiber in complex food packaging. This innovation opens new avenues when it comes to the use of fiber in food packaging. Huhtamaki’s high-precision technology means we can capture the very clear sustainability benefits of renewable wood fiber in an expanding array of packaging solutions that offer superior functionality, keep food safe and maintain its quality.
We see the development of this technology as a game changer milestone in sustainable packaging – and not only because the sustainability and food conservation features, but due to the new use case possibilities. We believe we will be able to replace for example caps and closures, which are today made of plastic or metals. Other potential applications are trays or containers that require lids that seal directly to the tray and are able to open/re-close.
More information about Huhtamaki’s proprietary high precision technology can be found here: Huhtamaki Fiber Solutions – The Future Redesigned.
For more information, please contact:
Richard Ali, VP Communications
Richard.email@example.com, Tel : +44 7387 261412
Huhtamaki is a key global provider of sustainable packaging solutions for consumers around the world. Our innovative products protect on-the-go and on-the-shelf food and beverages, ensuring hygiene and safety, driving accessibility and affordability, and helping prevent food waste. We embed sustainability in everything we do. We are committed to achieving carbon neutral production and designing all our products to be recyclable, compostable or reusable by 2030.
We are a participant in the UN Global Compact and EcoVadis has awarded Huhtamaki with the Gold medal for performance in sustainability. To play our part in managing climate change, we have set science-based targets that have been approved and validated by the Science-Based Targets Initiative.
With 100 years of history and a strong Nordic heritage, we operate in 37 countries and 114 operating locations around the world. Our values Care Dare Deliver guide our decisions and help our team of over 19,000 employees make a difference where it matters. Our 2021 net sales totaled EUR 3.6 billion. Huhtamaki Group is headquartered in Espoo, Finland and our parent company, Huhtamäki Oyj, is listed on Nasdaq Helsinki Ltd. Find out more about how we are protecting food, people and the planet at www.huhtamaki.com.
- Huhtamaki_compostable paper-based coffee capsule
- Huhtamaki President and CEO_Charles Heaulme
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t